On that point you're right: if the data is good, whenever it's released, all is forgiven. But I made, and maybe I'm not alone, a decent-sized investment decision based on release of Prurisol interim results prior to the end of Q3. It was a time-sensitive investment, probably ill-advised for a clinical-stage biotech, but until Q3 Ipix was and is clicking on all cylinders on meeting its declared milestones.
If the data is good, all is forgiven. Mostly. Stir that Kevetrin pot with care Krishna.
News 
Market Data 
Discover 
